{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:42:41Z","timestamp":1789756961663,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1124\/jpet.113.211904","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T03:13:32Z","timestamp":1389669212000},"page":"138-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacology of JNJ-42314415, a Centrally Active Phosphodiesterase 10A (PDE10A) Inhibitor: A Comparison of PDE10A Inhibitors with D2 Receptor Blockers as Potential Antipsychotic Drugs"],"prefix":"10.1016","volume":"349","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-2387","authenticated-orcid":false,"given":"Anton A.H.P.","family":"Megens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman M.R.","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen A.","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineke","family":"Fonteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke V.F.","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet","family":"Vanhoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.113.211904_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"issue":"Suppl 1","key":"10.1124\/jpet.113.211904_bib2","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0920-9964(12)70783-1","article-title":"Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia","volume":"136","author":"DeMartinis","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.113.211904_bib3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"Suppl","key":"10.1124\/jpet.113.211904_bib4","first-page":"S75","article-title":"Neuroleptic-induced hyperprolactinemia","volume":"35","author":"Dickson","year":"1999","journal-title":"Review 81 refs Schizophr Res"},{"key":"10.1124\/jpet.113.211904_bib5","doi-asserted-by":"crossref","first-page":"14273","DOI":"10.1523\/JNEUROSCI.1894-10.2010","article-title":"Influence of phasic and tonic dopamine release on receptor activation","volume":"30","author":"Dreyer","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.113.211904_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1052-5149(03)00089-3","article-title":"Positron emission tomography and single photon emission CT molecular imaging in schizophrenia","volume":"13","author":"Erritzoe","year":"2003","journal-title":"Neuroimaging Clin N Am"},{"key":"10.1124\/jpet.113.211904_bib7","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.113.211904_bib8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.211904_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0166-2236(90)90104-I","article-title":"Neurotransmitters and neuromodulators in the basal ganglia","volume":"13","author":"Graybiel","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.113.211904_bib10","doi-asserted-by":"crossref","first-page":"R509","DOI":"10.1016\/S0960-9822(00)00593-5","article-title":"The basal ganglia","volume":"10","author":"Graybiel","year":"2000","journal-title":"Curr Biol"},{"key":"10.1124\/jpet.113.211904_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.pharmthera.2005.12.001","article-title":"What has been learnt from study of dopamine receptors in Parkinson\u2019s disease?","volume":"111","author":"Hurley","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.113.211904_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/jpet.113.211904_bib13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543770903431050","article-title":"Patented PDE10A inhibitors: novel compounds since 2007","volume":"19","author":"Kehler","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.113.211904_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/13543776.17.2.147","article-title":"The potential therapeutic use of phosphodiesterase 10 inhibitors","volume":"17","author":"Kehler","year":"2007","journal-title":"Expert Opin Ther Patents"},{"key":"10.1124\/jpet.113.211904_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.110.173294","article-title":"Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington\u2019s disease","volume":"336","author":"Kleiman","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.211904_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.111.190702","article-title":"Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia","volume":"342","author":"Langlois","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.211904_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.113.211904_bib18","unstructured":"Lewi PJ, Niemegeers CJE, and Gypen LMJ (1977) First Hand Estimation of the Median ffective Dose (ED50) and its Confidence Interval, Assuming a Linear Log Dose-Response Function. Internal Report N123705\/1. Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica, Turnhoutseweg, Beerse, Belgium."},{"key":"10.1124\/jpet.113.211904_bib19","series-title":"Atypical Antipychotics","article-title":"Receptor profile of neuroleptics","author":"Leysen","year":"2000"},{"key":"10.1124\/jpet.113.211904_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","article-title":"Isolation and characterization of PDE10A, a novel human 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase","volume":"234","author":"Loughney","year":"1999","journal-title":"Gene"},{"key":"10.1124\/jpet.113.211904_bib21","first-page":"1582","article-title":"Parkinson\u2019s disease and D1 dopamine receptors","volume":"2","author":"Mailman","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.113.211904_bib22","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.113.211904_bib23","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/0024-3205(79)90096-1","article-title":"A systematic study of the pharmacological activities of dopamine antagonists","volume":"24","author":"Niemegeers","year":"1979","journal-title":"Life Sci"},{"key":"10.1124\/jpet.113.211904_bib24","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.113.211904_bib25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.neuropharm.2009.11.011","article-title":"Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo","volume":"58","author":"Sammut","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.113.211904_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1471-4159.2007.05152.x","article-title":"Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2","volume":"105","author":"Sano","year":"2008","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.113.211904_bib27","first-page":"17S","article-title":"Preclinical characterization of PDE10A inhibitors as putative antipsychotic agents","volume":"71","author":"Schmidt","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.113.211904_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.113.211904_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.113.211904_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.10.4.515","article-title":"Targeting the dopamine D2 receptor in schizophrenia","volume":"10","author":"Seeman","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/jpet.113.211904_bib31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/0023210-200822120-00002","article-title":"The role of phosphodiesterases in schizophrenia:therapeutic implications","volume":"22","author":"Siuciak","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.113.211904_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.113.211904_bib33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.113.211904_bib34","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.113.211904_bib35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2009.06004.x","article-title":"Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons","volume":"109","author":"Sotty","year":"2009","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.113.211904_bib36","series-title":"Encyclopedia of Statistical Science","first-page":"236","article-title":"Statistical methods in bioassay: estimation of relative potency from quantal responses","author":"Tsutakawa","year":"1982"},{"key":"10.1124\/jpet.113.211904_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2013.10.015","article-title":"Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications","volume":"77","author":"Uthayathas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.113.211904_bib38","series-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"237","article-title":"Adrenergic agonists and antagonists","author":"Westfall","year":"2006"},{"key":"10.1124\/jpet.113.211904_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/med.20130","article-title":"Dopamine D1 receptor ligands: where are we now and where are we going","volume":"29","author":"Zhang","year":"2009","journal-title":"Med Res Rev"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524272529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524272529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.113.211904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:11:31Z","timestamp":1739995891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524272529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0022356524272529"],"URL":"https:\/\/doi.org\/10.1124\/jpet.113.211904","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of JNJ-42314415, a Centrally Active Phosphodiesterase 10A (PDE10A) Inhibitor: A Comparison of PDE10A Inhibitors with D2 Receptor Blockers as Potential Antipsychotic Drugs","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.113.211904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}